drugset / Trial / NCT01220869

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

NCT01220869

Phase 3 Completed 110 enrolled Ferring Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

A phase III trial investigating the efficacy and safety of degarelix one-month depot in Taiwanese patients with prostate cancer.

Timeline

Start
2010-12
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 80 mg Subcutaneous

Indications